Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Closed 03-03 15:00:00

25.50

-0.64

-2.45%

High26.25	Low25.45	Vol19.75M
Open26.10	D1 Closing26.14	Amplitude3.06%
Mkt Cap68.09B	Tradable Cap54.01B	Total Shares2.67B
T/O509.00M	T/O Rate0.93%	Tradable Shares2.12B
P/B1.42	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.","latestPrice":25.5,"timestamp":1772521200000,"preClose":26.14,"halted":0,"volume":19749383,"delay":0,"changeRate":-0.0245,"floatShares":2118000000,"shares":2670000000,"eps":1.2293,"marketStatus":"Closed","change":-0.64,"latestTime":"03-03 15:00:00","open":26.1,"high":26.25,"low":25.45,"amount":509000000,"amplitude":0.0306,"askPrice":25.51,"askSize":74,"bidPrice":25.5,"bidSize":67,"shortable":0,"etf":0,"ttmEps":1.2293,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772587800000},"marketStatusCode":5,"adr":0,"adjPreClose":26.14,"symbolType":"stock","openAndCloseTimeList":[[1772501400000,1772508600000],[1772514000000,1772521200000]],"highLimit":28.75,"lowLimit":23.53,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.42,"roa":"--","peRate":20.743513,"roe":"5.3%","epsLYR":1.04,"committee":0.593395,"marketValue":68096000000,"turnoverRate":0.0093,"status":1,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":18.82,"timestamp":1772525309005,"preClose":19.34,"halted":0,"volume":3177984,"delay":0,"premium":"-34.60"},"floatMarketCap":54021000000},"requestUrl":"/m/hq/s/600196/tweets","defaultTab":"tweets","newsList":[{"id":"2614851152","title":"Shanghai Fosun Pharmaceutical (Group) Co. Ltd. held shareholder meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2614851152","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614851152?lang=en_us&edition=fundamental","pubTime":"2026-02-27 22:08","pubTimestamp":1772201327,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  Co. Ltd. held the 2026 first extraordinary general meeting, the 2026 first A shareholders’ class meeting and the 2026 first H shareholders’ class meeting on 27 February 2026. Shareholders approved proposals related to the spin-off of Fosun Adgenvax for an initial public offering of H shares and listing on the Main Board of the Hong Kong Stock Exchange, including the spin-off plan and proposal, the purpose and feasibility of the spin-off, maintenance of Shanghai Fosun Pharmaceutical’s independence and continuous operating capability, Fosun Adgenvax’s standardized operations capability, safeguarding shareholder and creditor interests, completeness and validity of procedures and documents, shareholdings of certain directors and senior management and affiliated parties in the company to be spun off, authorisation for the board to handle matters related to the spin-off, and the proposed assured entitlements to H shareholders in connection with the spin-off. At","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL7sBSbf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0183","00656","BK0187","BK1230","BK0060","BK0012","BK0188","BK0096","BK0239","600196","BK0196","BK0028"],"gpt_icon":0},{"id":"2614041518","title":"Fosun Pharma Gets Regulatory Nod for 6 Billion Yuan Bond Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2614041518","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614041518?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:42","pubTimestamp":1772109753,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  obtained approval from the China Securities Regulatory Commission to issue up to 6 billion yuan of bonds to professional investors, according to a Thursday Hong Kong bourse filing.The pharmaceutical firm can issue the bonds in multiple tranches within 24 months.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600196","BK1515","BK0239","US7Y.BOND","BK0187","BK1593","BK0196","BK0188","TMF","TLTW","BK1191","BK0096","US2Y.BOND","BK0012","BK0028","US5Y.BOND","02196","BK0060","US6M.BOND","US3Y.BOND","US30Y.BOND","BK0175","BK0183","US10Y.BOND","US12M.BOND"],"gpt_icon":0},{"id":"1176194664","title":"FOSUN PHARMA Secures Regulatory Approval for Bond Offering to Professional Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=1176194664","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176194664?lang=en_us&edition=fundamental","pubTime":"2026-02-26 18:40","pubTimestamp":1772102414,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) has announced that the company recently received approval from the China Securities Regulatory Commission (CSRC) for its application to issue science and technology innovation...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0012","BK0188","BK0196","BK0239","BK1593","BK0175","BK0060","600196","BK0187","02196","BK1191","BK1515","BK0096","BK0028"],"gpt_icon":0},{"id":"2614601967","title":"Shanghai Fosun Pharmaceutical  Says It Received Securities Regulator's Approval to Issue up to 6 Bln Yuan of Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2614601967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614601967?lang=en_us&edition=fundamental","pubTime":"2026-02-26 17:33","pubTimestamp":1772098420,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL4N3ZM0U4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0012","BK0028","BK0187","BK0188","BK0183","600196","BK0239","BK0196","BK0060","BK0175","BK0096"],"gpt_icon":0},{"id":"2614199380","title":"BRIEF-Shanghai Fosun Pharmaceutical Receives Regulatory Approval For Bond Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2614199380","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614199380?lang=en_us&edition=fundamental","pubTime":"2026-02-26 17:33","pubTimestamp":1772098420,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharmaceutical Receives Regulatory Approval For Bond IssuanceFeb 26  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:SAYS IT RECEIVED SECURITIES REGULATOR'S APPROVAL TO ISSUE UP TO 6 BILLION YUAN  OF BONDSSource textFurther company coverage: 600196.SS  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL4N3ZM0U4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0060","BK0183","BK0188","BK0187","BK0028","BK0196","BK0239","BK0096","600196","BK0012"],"gpt_icon":0},{"id":"2614045081","title":"Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045081","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045081?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:23","pubTimestamp":1772022189,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  unit Shanghai Fosun Pharmaceutical Industrial Development obtained clinical trial approval for Luvometinib Tablets from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The drug will be tested in combination with Anlotinib for the treatment of patients with KRAS-mutant advanced non-small cell lung cancer.The subsidiary intends to begin the phase II study in China when the relevant conditions are fulfilled.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","02196","BK1515","BK0239","600196","BK0187","BK0196","BK0188","BK1191","BK0183","BK0028","BK1593","BK0096","BK0012","BK0060"],"gpt_icon":0},{"id":"2614707606","title":"Shanghai Fosun Pharma - Units Gets Approval From Nmpa for Clinical Trial of Luvometinib Tablets in Combination With Anlotinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2614707606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614707606?lang=en_us&edition=fundamental","pubTime":"2026-02-25 17:44","pubTimestamp":1772012689,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL0QF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0028","BK0096","BK0183","BK0239","BK0175","BK0188","BK0196","BK0187","600196","BK0060","BK0012"],"gpt_icon":0},{"id":"2614707674","title":"Fosun Pharma Industrial Wins NMPA Approval for Luvometinib Combo Phase II NSCLC Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2614707674","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614707674?lang=en_us&edition=fundamental","pubTime":"2026-02-25 17:43","pubTimestamp":1772012639,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Industrial Development Company Limited, a subsidiary of Shanghai Fosun Pharmaceutical  Co. Ltd., received approval from China’s National Medical Products Administration to conduct a Phase II clinical trial of Fumaining  in combination with anlotinib for KRAS-mutant advanced non-small cell lung cancer in China. The drug, a self-developed MEK1/2 selective inhibitor, is already marketed in China for Langerhans cell histiocytosis and certain neurofibromatosis type 1 cases, and is also being studied for additional indications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Serv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL9M07nz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0028","BK0187","BK0188","BK0183","00656","600196","BK0239","BK0196","BK0060","BK0175","BK0096","BK1230"],"gpt_icon":0},{"id":"2614577290","title":"Fosun Pharmaceutical Amends Drug Licensing Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2614577290","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614577290?lang=en_us&edition=fundamental","pubTime":"2026-02-25 13:39","pubTimestamp":1771997956,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) amended its licensing agreements for anti-cancer drug serplulimab.Subsidiary Henlius terminated its exclusive commercialization agreement with KGbi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0060","BK0175","BK0183","BK1593","BK0239","BK0012","BK0096","BK1191","BK0188","BK0187","02196","600196","BK0196","BK1515"],"gpt_icon":0},{"id":"2611126156","title":"Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2611126156","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611126156?lang=en_us&edition=fundamental","pubTime":"2026-02-13 19:31","pubTimestamp":1770982277,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  said unit Jinzhou Avanc Pharmaceutical's drug registration application of Moxetomidate Hydrochloride Injection was accepted by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The indication under this application is for the induction and maintenance of anesthesia during short surgical procedures.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600196","BK0188","BK0239","BK0175","BK0028","BK0196","BK1593","BK0060","BK0012","BK0187","BK1191","02196","BK1515","BK0183","BK0096"],"gpt_icon":0},{"id":"1192481164","title":"FOSUN PHARMA's Cisplatin Injection Marketing Application Accepted for Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1192481164","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192481164?lang=en_us&edition=fundamental","pubTime":"2026-02-13 17:54","pubTimestamp":1770976456,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) announced that the marketing authorization application for Cisplatin Injection, submitted by its controlling subsidiary, Gismee (Wuhan) Pharmaceutical Co., Ltd., has been...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK0188","BK1515","BK0183","BK0028","BK1593","BK0187","BK0096","BK0196","BK0175","BK0060","600196","BK0239","02196","BK0012"],"gpt_icon":0},{"id":"2611309111","title":"Shanghai Fosun Pharma -  Drug Registration Application of Moxetomidate Hydrochloride Injection Accepted by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2611309111","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611309111?lang=en_us&edition=fundamental","pubTime":"2026-02-13 17:43","pubTimestamp":1770975836,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nFWN3Z905A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0188","BK0183","BK0028","BK0187","BK0096","BK0196","BK0175","BK0060","600196","BK0239","BK0012"],"gpt_icon":0},{"id":"2611912130","title":"Shanghai Fosun Pharmaceutical Subsidiary Drug Registration Application Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=2611912130","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611912130?lang=en_us&edition=fundamental","pubTime":"2026-02-13 17:43","pubTimestamp":1770975835,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  Co., Ltd. announced that a subsidiary's drug registration application has been accepted by the relevant regulatory authority. The company disclosed this information pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. Further details regarding the specific drug or subsidiary were not provided in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL5CJBzC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0183","00656","BK0187","BK1230","BK0060","BK0012","BK0188","BK0096","BK0239","600196","BK0196","BK0028"],"gpt_icon":0},{"id":"2611747189","title":"Fosun Pharma Gets Regulatory Approval for Myeloma Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2611747189","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611747189?lang=en_us&edition=fundamental","pubTime":"2026-02-13 12:30","pubTimestamp":1770957008,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  obtained China's regulatory approval for first phase clinical trials of subcutaneous injection HLX15-SC for multiple myeloma treatment.HLX15 is a daratumumab biosimilar independently developed by the company, according to a Thursday filing with the Shanghai bourse.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0196","BK0060","BK0012","BK1593","BK1191","BK1515","BK0239","BK0096","02196","BK0175","BK0188","BK0183","600196","BK0187"],"gpt_icon":0},{"id":"2610174646","title":"Fosun Pharma Unit Gets China Acceptance for Application of Local Anaesthetic","url":"https://stock-news.laohu8.com/highlight/detail?id=2610174646","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610174646?lang=en_us&edition=fundamental","pubTime":"2026-02-10 18:43","pubTimestamp":1770720239,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  said the drug registration application of Tetracaine Hydrochloride Gel was accepted by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The application was submitted by Shanghai Zhaohui Pharmaceutical, a unit of the pharmaceutical firm.The drug is intended to be used as a percutaneous local anaesthetic for the skin prior to venepuncture or venous cannulation.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK1191","BK0183","BK0060","BK0175","BK1515","BK1593","BK0028","BK0096","600196","BK0239","BK0187","02196","BK0188","BK0012"],"gpt_icon":0},{"id":"2610645539","title":"BRIEF-Shanghai Fosun Pharma Says Drug Registration Application Of Tetracaine Hydrochloride Gel Accepted By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2610645539","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610645539?lang=en_us&edition=fundamental","pubTime":"2026-02-10 18:07","pubTimestamp":1770718073,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma Says Drug Registration Application Of Tetracaine Hydrochloride Gel Accepted By NMPAFeb 10  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:DRUG REGISTRATION APPLICATION OF TETRACAINE HYDROCHLORIDE GEL ACCEPTED BY CHINA'S NMPAFurther company coverage: 600196.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z60MB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0028","BK0183","BK0012","BK0196","BK0239","BK0188","BK0175","BK0187","BK0096","600196"],"gpt_icon":0},{"id":"2610487606","title":"Shanghai Fosun Pharma -  Drug Registration Application of Tetracaine Hydrochloride Gel Accepted by China's Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2610487606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610487606?lang=en_us&edition=fundamental","pubTime":"2026-02-10 17:36","pubTimestamp":1770716187,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z60MB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0028","BK0196","BK0060","BK0012","BK0239","BK0096","BK0175","BK0188","BK0183","600196","BK0187"],"gpt_icon":0},{"id":"2610716648","title":"Shanghai Fosun Pharmaceutical Subsidiary Drug Registration Application Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=2610716648","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610716648?lang=en_us&edition=fundamental","pubTime":"2026-02-10 17:36","pubTimestamp":1770716182,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  Co., Ltd. announced that a drug registration application submitted by one of its subsidiaries has been accepted by the relevant regulatory authority. The company noted that the acceptance of the application is an early step in the regulatory process and emphasized that the drug is still subject to further requirements, including passing GMP compliance inspections and obtaining final drug registration approval before commercial production can commence. Fosun Pharma also noted that the acceptance of the application is not expected to have a material impact on the Group's results at this stage, and highlighted potential uncertainties related to future sales performance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL8r4rD7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0096","BK0012","600196","BK1230","BK0239","BK0183","BK0028","BK0187","00656","BK0060","BK0196","BK0188"],"gpt_icon":0},{"id":"1103851342","title":"FOSUN PHARMA's Cyclophosphamide Injection Application Accepted for Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1103851342","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103851342?lang=en_us&edition=fundamental","pubTime":"2026-02-05 17:31","pubTimestamp":1770283892,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) announced that its controlled subsidiary, Gismee (Wuhan) Pharmaceutical Co., Ltd., recently had the drug registration application for Cyclophosphamide Injection accepted by the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1191","600196","BK0187","BK0239","BK0175","BK0183","BK0012","BK1593","BK0096","BK0196","BK0028","BK0060","BK0188","02196"],"gpt_icon":0},{"id":"2609320698","title":"Shanghai Fosun Pharmaceutical Subsidiary Drug Registration Application Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=2609320698","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609320698?lang=en_us&edition=fundamental","pubTime":"2026-02-05 17:26","pubTimestamp":1770283613,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  Co. Ltd. announced that a subsidiary's drug registration application has been accepted by the relevant regulatory authorities. The acceptance marks an initial step in the regulatory review process, but the drug will require further approval before commercial production can begin. The company noted that this acceptance is not expected to have a material impact on its financial results at this stage, and highlighted that future sales performance of the product may be influenced by factors such as market demand, competition, and sales channels. No other beneficiary organizations were mentioned in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. publishe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL26tsz0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","BK0188","BK0183","BK0028","BK1230","BK0187","BK0096","BK0196","BK0175","BK0060","600196","BK0239","BK0012"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","stockEarnings":[{"period":"1week","weight":-0.0162},{"period":"1month","weight":-0.0199},{"period":"3month","weight":-0.0351},{"period":"6month","weight":-0.156},{"period":"1year","weight":0.0582},{"period":"ytd","weight":-0.0132}],"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"267042万元","compareEarnings":[{"period":"1week","weight":0.0246},{"period":"1month","weight":0.0157},{"period":"3month","weight":0.0731},{"period":"6month","weight":0.0968},{"period":"1year","weight":0.2595},{"period":"ytd","weight":0.0539}],"survey":"　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。","serverTime":1772536801339,"listedPrice":7.15,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.,600196,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎国际,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股价,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股市,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票价格,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票交易,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票购买,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction